The purpose of the proposed pilot study is to evaluate the effects of a soy protein isolate with naturally occurring isoflavones on the properties of HDL-C (total HDL-C, HDL particle size and HDL function), central blood pressure, and indices of arterial stiffness.
The investigators propose to conduct a randomized three-period, crossover study to evaluate the effect of soy protein supplementation on HDL function. To ensure that there are no effects of treatment order on outcome measures, subjects will be randomized to a treatment sequence. Healthy males and females (n = 20; 35 to 60 years of age) with systolic blood pressure greater than 120 mm Hg and/or diastolic blood pressure greater than 80 mm Hg will be recruited for this study. Subjects will undergo 3 treatment periods in random order. These treatment periods will include: A) 25 g/d soy protein powder; B) 50 g/d soy protein powder; C) 0 g/d protein powder (control). Each treatment will be provided for 6 weeks separated by a 2-week break between treatment periods. All subjects will be encouraged to maintain body weight and physical activity levels during the study.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Enrollment
20
Participants will consume 25g soy protein powder daily for a 6 week treatment period.
Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
Participants will consume 50g soy protein powder daily for a 6 week treatment period.
Penn State University
University Park, Pennsylvania, United States
HDL function (RCT) as measured by cholesterol efflux.
Prior to start of intervention
Time frame: Baseline
HDL function (RCT) as measured by cholesterol efflux.
End of treatment 1
Time frame: Week 6
HDL function (RCT) as measured by cholesterol efflux.
End of treatment 2
Time frame: Week 14
HDL function (RCT) as measured by cholesterol efflux.
End of treatment 3
Time frame: Week 22
HDL particle size
Prior to start of intervention
Time frame: Baseline
HDL particle size
End of treatment 1
Time frame: Week 6
HDL particle size
End of treatment 2
Time frame: Week 14
HDL particle size
End of treatment 3
Time frame: Week 22
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.